Insulet (NASDAQ:PODD) Price Target Raised to $386.00

Insulet (NASDAQ:PODD) had its price target hoisted by Leerink Partners from $385.00 to $386.00 in a report issued on Friday,MarketScreener reports. They currently have an outperform rating on the medical instruments supplier’s stock.

A number of other research analysts have also recently commented on the stock. Truist Financial boosted their target price on shares of Insulet from $365.00 to $390.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. JPMorgan Chase & Co. raised their price target on shares of Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. UBS Group upgraded Insulet from a “neutral” rating to a “buy” rating and raised their target price for the company from $355.00 to $400.00 in a research note on Wednesday. Oppenheimer raised their target price on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research report on Monday, September 8th. Finally, Barclays boosted their price target on shares of Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average target price of $379.45.

Insulet Trading Up 5.8%

Shares of PODD opened at $331.17 on Friday. The firm has a market capitalization of $23.30 billion, a P/E ratio of 100.66, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet has a twelve month low of $230.05 and a twelve month high of $354.88. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock’s fifty day simple moving average is $322.22 and its 200 day simple moving average is $315.44.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same quarter in the prior year, the company earned $1.08 EPS. The company’s revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities research analysts forecast that Insulet will post 3.92 earnings per share for the current year.

Insider Activity

In other Insulet news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.39% of the stock is currently owned by corporate insiders.

Institutional Trading of Insulet

Several large investors have recently modified their holdings of the company. Zions Bancorporation National Association UT acquired a new position in shares of Insulet during the first quarter worth approximately $26,000. SouthState Corp grew its position in Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 76 shares during the last quarter. True Wealth Design LLC grew its holdings in shares of Insulet by 288.0% during the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 72 shares during the last quarter. Kozak & Associates Inc. bought a new stake in Insulet during the 2nd quarter worth about $32,000. Finally, Golden State Wealth Management LLC grew its stake in shares of Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.